Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Fexofenadine Hydrochloride,Pseudoephedrine

            Therapeutic Area: Immunology Product Name: Diregura

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: LTL Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 04, 2020

            Details:

            LTL Pharma will take over the Japanese marketing authorization (MA) of Sanofi’s anti-allergic medicine Diregura (fexofenadine + pseudoephedrine).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Inolimomab

            Therapeutic Area: Immunology Product Name: Leukotac

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 14, 2021

            Details:

            ElsaLys Biotech confirmed that The French National Agency for the Medicines and Health Products Safety (ANSM) has renewed the Temporary Authorisation for Use (ATU) so-called cohort ATU (cATU) for inolimomab (LEUKOTAC®) on December 24, 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Inolimomab

            Therapeutic Area: Immunology Product Name: Leukotac

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bpifrance

            Deal Size: $4.0 million Upfront Cash: Undisclosed

            Deal Type: Funding January 19, 2021

            Details:

            The Silikotac Program consortium, consisting of ElsaLys Biotech, Novadiscovery and two expert academic teams, has been awarded €3.35 million in non-dilutive funding by Bpifrance to support development of inolimomab in graft-versus-host disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Triamcinolone Acetonide

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Medexus Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 18, 2020

            Details:

            Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones.